T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells Conference Paper

   


Authors: O'Reilly, R. J.; Koehne, G.; Hasan, A. N.; Doubrovina, E.; Prockop, S.
Title: T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells
Conference Title: 7th International Symposium: Haploidentical Hematopoietic Stem Cell Transplantation
Abstract: Allogeneic hematopoietic cell transplants adequately depleted of T-cells can reduce or prevent acute and chronic GVHD in both HLA-matched and haplotype-disparate hosts, without post-transplant prophylaxis with immunosuppressive drugs. Recent trials indicate that high doses of CD34+ progenitors from G-CSF mobilized peripheral blood leukocytes isolated and T-cell depleted by immunoadsorption to paramagnetic beads, when administered after myeloablative conditioning with TBI and chemotherapy or chemotherapy alone can secure consistent engraftment and abrogate GVHD in patients with acute leukemia without incurring an increased risk of a recurrent leukemia. Early clinical trials also indicate that high doses of in vitro generated leukemia-reactive donor T-cells can be adoptively transferred and can induce remissions of leukemia relapse without GVHD. Similarly, virus-specific T-cells generated from the transplant donor or an HLA partially matched third party, have induced remissions of Rituxan-refractory EBV lymphomas and can clear CMV disease or viremia persisting despite antiviral therapy in a high proportion of cases. Analyses of treatment responses and failures illustrate both the advantages and limitations of donor or banked, third party-derived T-cells, but underscore the potential of adoptive T-cell therapy in the absence of ongoing immunosuppression. © 2015 Macmillan Publishers Limited All rights reserved.
Keywords: cancer chemotherapy; treatment response; treatment failure; busulfan; fludarabine; nonhuman; methotrexate; rituximab; recurrence risk; t lymphocyte; cd34 antigen; chemoprophylaxis; cyclophosphamide; melphalan; in vitro study; thiotepa; stem cell; haplotype; acute graft versus host disease; acute leukemia; chronic graft versus host disease; engraftment; hla matching; myeloablative conditioning; whole body radiation; donor; lymphoma; cell isolation; graft versus host reaction; stem cell mobilization; allogeneic hematopoietic stem cell transplantation; adoptive transfer; t cell depletion; immunosuppressive treatment; tacrolimus; leukemia relapse; granulocyte colony stimulating factor; leukocyte; cytomegalovirus infection; adoptive immunotherapy; clofarabine; epstein barr virus; immunosuppressive agent; leukemia remission; antiviral therapy; organ donor; viremia; human; priority journal; article; immunoadsorption; virus specific t cell
Journal Title Bone Marrow Transplantation
Volume: 50
Issue: Suppl. 2
Conference Dates: 2014 Feb 9-10
Conference Location: Rehovot, Israel
ISBN: 0268-3369
Publisher: Nature Publishing Group  
Date Published: 2015-06-01
Start Page: S43
End Page: S50
Language: English
DOI: 10.1038/bmt.2015.95
PROVIDER: scopus
PUBMED: 26039207
PMCID: PMC4787269
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84930428303&partnerID=40&md5=dc9e5d2c343a0423b2d63542bbef7dae
Notes: Export Date: 2 July 2015 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Susan E Prockop
    262 Prockop
  2. Guenther Koehne
    194 Koehne
  3. Ekaterina Doubrovina
    101 Doubrovina
  4. Aisha Nasreen Hasan
    56 Hasan
  5. Richard O'Reilly
    748 O'Reilly
Related MSK Work